One of our hopes for this blog is that we can blend the strategic (China’s healthcare reforms) with the practical (how to adjust your pricing or distribution strategy as a pharma or device company).  Emphasizing only the former runs the risk of constantly talking up the opportunity inherent with the massive influx of government-led investment [...]

For life science companies building and executing a market access strategy in China, the question is rarely whether or not a big enough market exists to justify their efforts; rather, the most pressing question is what they will have to trade in order to open the market itself.  The question of what the exchange is [...]

As part of the recently completed report on China’s healthcare system by McKinsey & Company, I had the pleasure of speaking with Franck Le Deu, the head of McKinsey’s Greater China Healthcare practice.  At a little under 200 pages, the report is highly recommended for anyone who wants to understand how China’s healthcare reforms are [...]